{"id":"gestonorone","rwe":[{"pmid":"33219367","year":"2021","title":"Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.","finding":"","journal":"Prostate cancer and prostatic diseases","studyType":"Clinical Study"},{"pmid":"9837693","year":"1998","title":"Treatment with progesterone analogues decreases macrophage Fcgamma receptors expression.","finding":"","journal":"Clinical immunology and immunopathology","studyType":"Clinical Study"},{"pmid":"8462531","year":"1993","title":"Studies for a genotoxic potential of some endogenous and exogenous sex steroids. I. Communication: examination for the induction of gene mutations using the Ames Salmonella/microsome test and the HGPRT test in V79 cells.","finding":"","journal":"Environmental and molecular mutagenesis","studyType":"Clinical Study"},{"pmid":"1722627","year":"1991","title":"[Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].","finding":"","journal":"Hinyokika kiyo. Acta urologica Japonica","studyType":"Clinical Study"},{"pmid":"2428120","year":"1986","title":"[Medical therapy of benign prostatic hyperplasia: cyproterone acetate vs gestonorone caproate].","finding":"","journal":"Minerva urologica e nefrologica = The Italian journal of urology and nephrology","studyType":"Clinical Study"}],"tags":[{"label":"gestonorone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"G03DA01","category":"atc"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["gestonorone"],"offLabel":[],"synonyms":["gestonorone"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"gestonorone","explanation":"Imagine your body's hormones as a team of workers. Progesterone is like a manager that helps coordinate their efforts. Gestonorone is like a new manager that comes in and changes the way the team works, which can affect how your body functions.","oneSentence":"Gestonorone works by binding to the progesterone receptor, influencing hormone-sensitive processes in the body.","technicalDetail":"Gestonorone exerts its effects by selectively binding to the progesterone receptor, a nuclear receptor that regulates gene expression in response to progesterone. This interaction can influence various physiological processes, including reproductive and metabolic functions."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4563","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=gestonorone","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:44:43.531498","biosimilars":[],"competitors":[{"drugName":"medroxyprogesterone","drugSlug":"medroxyprogesterone","fdaApproval":"1959-06-18","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"hydroxyprogesterone caproate","drugSlug":"hydroxyprogesterone-caproate","fdaApproval":"1975-10-03","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"progesterone","drugSlug":"progesterone","fdaApproval":"1976-02-04","patentExpiry":"Jan 21, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"gestonorone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"medroxyprogesterone","brandName":"medroxyprogesterone","genericName":"medroxyprogesterone","approvalYear":"1959","relationship":"same-class"},{"drugId":"hydroxyprogesterone-caproate","brandName":"hydroxyprogesterone caproate","genericName":"hydroxyprogesterone caproate","approvalYear":"1975","relationship":"same-class"},{"drugId":"progesterone","brandName":"progesterone","genericName":"progesterone","approvalYear":"1976","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"H4G605B7VP","RXNORM":"4793","UMLSCUI":"C0017508","ChEMBL_ID":"CHEMBL3707212","DRUGBANK_ID":"DB13230","PUBCHEM_CID":"102210","SNOMEDCT_US":"395980001"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":28,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"G03DA01","allCodes":["G03DA01","L02AB03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2021 Jun","pmid":"33219367","title":"Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.","journal":"Prostate cancer and prostatic diseases"},{"date":"1998 Dec","pmid":"9837693","title":"Treatment with progesterone analogues decreases macrophage Fcgamma receptors expression.","journal":"Clinical immunology and immunopathology"},{"date":"1993","pmid":"8462531","title":"Studies for a genotoxic potential of some endogenous and exogenous sex steroids. I. Communication: examination for the induction of gene mutations using the Ames Salmonella/microsome test and the HGPRT test in V79 cells.","journal":"Environmental and molecular mutagenesis"},{"date":"1991 Nov","pmid":"1722627","title":"[Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].","journal":"Hinyokika kiyo. Acta urologica Japonica"},{"date":"1986 Apr-Jun","pmid":"2428120","title":"[Medical therapy of benign prostatic hyperplasia: cyproterone acetate vs gestonorone caproate].","journal":"Minerva urologica e nefrologica = The Italian journal of urology and nephrology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"gestonorone","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Gestonorone is a small molecule gestagen, a type of steroid hormone, that is currently owned by an unknown entity. Its target and exact mechanism of action are not well-documented, but it is believed to work by interacting with the progesterone receptor. Gestonorone is not FDA-approved for any indications, and its commercial status, including whether it is patented or generic, is unknown. As a result, there is limited information available on its safety profile, including its half-life, bioavailability, and potential side effects. Further research is needed to fully understand the properties and potential uses of gestonorone.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}